(April 11, 2024, 11:05 AM EDT) -- BOSTON — A federal judge in Massachusetts dismissed a putative class complaint filed by investors against a biopharmaceutical company and certain of its executives, finding that the investors did not substantiate their claim that the company issued false and misleading statements about a gene therapy program it was testing before the Food and Drug Administration ordered a hold on testing....